Erica Rogers - Nov 11, 2021 Form 4 Insider Report for Silk Road Medical Inc (SILK)

Role
President and CEO, Director
Signature
/s/Mhairi Jones, by power of attorney
Stock symbol
SILK
Transactions as of
Nov 11, 2021
Transactions value $
-$891,543
Form type
4
Date filed
11/15/2021, 05:14 PM
Previous filing
Oct 12, 2021
Next filing
Nov 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SILK Common Stock Options Exercise $8.38K +5.74K +4.35% $1.46* 138K Nov 11, 2021 Direct F1
transaction SILK Common Stock Sale -$291K -5.74K -4.16% $50.64 132K Nov 11, 2021 Direct F1, F2
transaction SILK Common Stock Options Exercise $16K +10K +7.57% $1.60* 142K Nov 11, 2021 Direct F1
transaction SILK Common Stock Sale -$506K -10K -7.04% $50.64 132K Nov 11, 2021 Direct F1, F2
transaction SILK Common Stock Sale -$119K -2.36K -1.79% $50.47 130K Nov 11, 2021 Direct F3
holding SILK Common Stock 83.8K Nov 11, 2021 Trustees of The Surace/Rogers Family Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SILK Option (right to buy) Options Exercise $0 -5.74K -100% $0.00* 0 Nov 11, 2021 Common Stock 5.74K $1.46 Direct F1, F5
transaction SILK Option (right to buy) Options Exercise $0 -10K -5.47% $0.00 173K Nov 11, 2021 Common Stock 10K $1.60 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021.
F2 This transaction was executed in multiple trades at price ranging from $49.31 to $51.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on August 20, 2021.
F4 These shares are held directly by Kevin J. Surace and Erica J. Rogers, as Trustees of The Surace Rogers Family Trust.
F5 All of the shares subject to this option are fully vested and exercisable as of the date hereof.